SUMMARY AND EXPLANATION
C-Reactive protein (CRP) is an alpha globulin with a molecular mass of approximately 110,000 to 140,000 daltons, and is composed of five identical subunits, which are noncovalently assembled as a cyclic pentamer. CRP is synthesized in the liver and is normally present as a trace constituent of serum or plasma at levels less than 0.3 mg/dl. CRP is one of the acute-phase proteins, the serum or plasma levels of which rise during general, nonspecific response to a wide variety of diseases. Although the detection of elevated levels of CRP in the serum is not specific for any particular disease, it is a useful indicator of inflammatory processes. Additionally, measurement of CRP by high-sensitivity C reactive protein test may add to the predictive value of other cardiac markers (myoglobin, creatine-kinase-MB, troponin I and T), which are used to assess the risk of cardiovascular and peripheral vascular disease. Inflammation in the arteries may play a role in heart disease and HS-CRP can determine heart disease risk in those with undetected heart disease and risk of complications for those who have already had a heart event.
||96 Tests (12x8 breakable strip wells)|
|Standard range||0.005-0.1 µg/ml|
|Sample volume||5 µl/well|
|Application||The Calbiotech High Sensitivity C-Reactive Protein ELISA Kit is intended for the quantitative determination of C-reactive protein (CRP) in human serum or plasma.|
The Calbiotech CRP kit is a solid phase direct sandwich ELISA. The samples and anti-CRP-HRP conjugate are added to the wells coated with MAb to CRP. CRP in the patient’s serum binds to anti-CRP MAb on the well and the anti-CRP second antibody then binds to CRP. Unbound protein and HRP conjugate are washed off by wash buffer. Upon the addition of the substrate, the intensity of color is proportional to the concentration of CRP in the samples. A standard curve is prepared relating color intensity to the concentration of the CRP in the C Reactive Protein Test.
|Storage and Stability||Product should be stored at 2-8 °C. Product is stable for 24 months from the date of manufacturing.|
|Precautions||For research use only. Not for use in diagnostic procedures.|
1. Schultz, D.R., and Arnold P.I.: “Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, glycoprotein, and fibrinogen.” Seminars in Arthritis and Rheumatism 20: 129-147, 1990.
2. Kindmark, C.O.: The Concentration of C-reactive protein in Sera from Healthy Individuals. Scand J Clin Lab Invest, 29: 407- 411, 1972.
3. Dowling, P., and Cook, S.: Immune events in demyelinating disease. In Wolfgang, F., Ellison, G.W., Stevens J.G., and Andrew, J.M. (eds.): Multiple sclerosis. Academic Press Inc., New York, 269-277, 1972.
4. YUDKIN, J.S., ET. AL.: C-REACTIVE PROTEIN IN HEALTHY SUBJECTS: ASSOCIATION WITH OBESITY, INSULIN RESISTANCE, AND ENDOTHELIAL DYSFUNCTION. A POTENTIAL ROLE FOR CYTOKINES ORIGINATING FROM ADIPOSE TISSUE? ARTERIOSCLER THROMB VASC BIOL 19:972-8, 1999.
5. Kushner, I., Rzewnicki, D.L.: The acute phase response: General aspects. Bailliere’s Clinical Rheumatology 8: 513-530, 1994.
6. Macy, E.M., Hayes, T.E., and Tracy, R.P.: Variability in the measurement of C-reactive protein in healthy subjects: implications for reference interval and epidemiological applications. Clin Chem, 43;1:52-58, 1997.
7. Hedlund, P.: Clinical and experimental studies on C-reactive protein (acute phase protein). Thesis Acta Med Scand, 128 (Suppl, 361):1-71, 1961.
8. Hedlund, P.: The appearance of acute phase protein in various diseases. Acta Med Scand, 128, (Suppl,196): 579-601, 1947.
9. Morley, J.J., Kushner, I.: Serum C-reactive Protein Levels. in: Kushner, I., Volanakis, J.E., and Gerwutz, H., eds., C-Reactive Protein and the Plasma Protein Response to Tissue Injury. Annals of N.Y. Acad Sci, 389: 406-417, 1982.